Urolithiasis Management Devices Market Analysis By Treatment Type (Extracorporeal Shock Wave Lithotripsy (Eswl), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy, Other Treatments (Watchful Waiting, Parathyroid Gland Surgery)), By End Use (Hospitals & Clinics, Ambulatory Surgical Centers), And Segment Forecasts To 2024

Published: Oct, 2016 | Pages: 115 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)

The global urolithiasis management devices market was valued at USD 1.27 billion in 2015 and is expected to be valued at USD 1.93 billion by 2024. The alarming growth in the incidence rate of urinary stones, over the years, is responsible for the advancements in the treatment options. European Association of Urology states that it is one of the most common lifestyle disorders with a 10% prevalence rate and requires a systematic treatment approach.

Urolithiasis means formation of stones in the urinary system, mainly including the kidney, ureters, and the bladder. It is a major healthcare concern in the high end countries such as the U.S., Canada, and Germany with a recurrence rate of 50% in most of the cases. Urolithiasis can be managed with the help of lifestyle changes, controlled diet, or basic medication. However, various treatment approaches need to be adopted for the removal of large stones that cause severe pain. Depending upon the stone size, location in the body, and anatomical variations in the urogenital tract, invasive or noninvasive stone removal procedures are available. For instance, smaller stones can be tackled with external shock waves (extracorporeal shock wave lithotripsy), while larger stones can be removed through surgeries (intracorporeal lithotripsy or percutaneous nephrolithotomy).

Smaller stones generally do not require surgical interventions and can be cured with the help of medication and a healthy diet. However, larger stones necessitate different approaches for their elimination. Extracorporeal lithotripsy is one of the common treatments employed for stone elimination and held a majority market share in the year 2015. Intracorporeal lithotripsy treatments spot and reduce the stones to smaller pieces with the help of endoscopy. For the disintegration of stones, ultrasound or laser techniques are used to enable the passage of smaller fragments through the urinary system. Owing to the effective stone-free rate offered by intracorporeal lithotripsy, it is likely to be preferred as a treatment option during the forecast period.

Furthermore, percutaneous nephrolithotomy is a surgical approach deployed to eliminate larger stones where extracorporeal or intracorporeal lithotripsies prove to be ineffective and typically require a week's hospitalization.

Ambulatory surgical centers are gaining popularity over traditional hospital and clinic settings due to the time and cost saving benefits. As a result, this end-use segment is expected to record a lucrative growth rate during the forecast period. Introduction of novel surgical technologies, such as endoscopy and micro accessories including guidewires, scalpels, and baskets, to effectively expel stones from the urinary system in a short time has enhanced the overall acceptability of minimally invasive surgeries.

Further Key Findings From the Study Suggest:

Urinary stones are highly prevalent worldwide with a 15% global target population and the recurrence rate of 50%. Men are more susceptible to developing renal stones than women.

Adoption and acceptance of intracorporeal lithotripsy contributed to more than 95% stone-free rate, which will render it the most preferred alternative over extracorporeal and subcutaneous treatments. On the other hand, ambulatory surgical centers will grow at a higher rate due to the associated benefits of lower cost and shorter perioperative time.

The upward trend in the adoption of sedentary lifestyle coupled with increased consumption of unhealthy food in the developed countries is responsible for the rising incidence of kidney stones. Ambulatory surgical service providers are expected to experience a surge in the treatment demand as a result of the unhealthy lifestyle changes, especially in the developed countries.

 Table of Contents

Chapter 1 Methodology & Scope
                    1.1 Research Methodology
                    1.2 Research Scope & Assumptions
                    1.3 List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Market Summary

Chapter 4 Market Variables, Trends& Scope
                    4.1 Market Segmentation & Scope
                        4.1.1 Market Driver Analysis 
                        4.1.2 Market Restraint Analysis
                    4.2 Penetration & Growth Prospect Mapping
                    4.3 Urolithiasis Management Devices Market - SWOT Analysis, By Factor (political & legal, economic and technological)
                    4.4 Industry Analysis - Porter's

Chapter 5 Market Categorization 1: Treatment Type Estimates & Trend Analysis
                    5.1 Urolithiasis Management Devices market: Treatment Type movement analysis
                    5.2 Extracorporeal Shock Wave Lithotripsy (ESWL)
                        5.2.1 Extracorporeal shock wave lithotripsy (ESWL) market, 2013 - 2024 (USD Million)
                    5.3 Intracorporeal Lithotripsy
                        5.3.1 Intracorporeal lithotripsy market, 2013 - 2024 (USD Million)
                    5.4 Percutaneous Nephrolithotomy
                        5.4.1 Percutaneous nephrolithotomy market, 2013 - 2024 (USD Million)
                    5.5 Other Treatments
                        5.5.1 Other treatments market, 2013 - 2024 (USD Million)

Chapter 6 Market Categorization 2: End-Use Estimates & Trend Analysis
                    6.1 Urolithiasis Management Devices market: End-Use movement analysis
                    6.2 Hospitals & Clinics
                        6.2.1 Hospitals & Clinics market, 2013 - 2024 (USD Million)
                    6.3 Ambulatory Surgical Centers
                        6.3.1 Ambulatory Surgical Centers market, 2013 - 2024 (USD Million)

Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Treatment Type, and End-Use
                    7.1 Urolithiasis Management Devices market share by region, 2013 & 2024
                    7.2 North America
                        7.2.1 U.S.
                        7.2.2 Canada
                    7.3 Europe
                        7.3.1 UK
                        7.3.2 Germany
                    7.4 Asia Pacific
                        7.4.1 Japan
                        7.4.2 China
                        7.4.3 India
                    7.5 Latin America
                        7.5.1 Mexico
                        7.5.2 Brazil
                    7.6 MEA
                        7.6.1 South Africa

Chapter 8 Competitive Landscape
                    8.1 Strategy framework
                    8.2 Company Profiles
                        8.2.1 Allengers Medical Systems Ltd.
                             8.2.1.1 Company Overview
                             8.2.1.2 Financial Performance
                             8.2.1.3 Product Benchmarking
                             8.2.1.4 Strategic Initiatives
                        8.2.2 Boston Scientific Corporation
                             8.2.2.1 Company Overview
                             8.2.2.2 Financial Performance
                             8.2.2.3 Product Benchmarking
                             8.2.2.4 Strategic Initiatives
                        8.2.3 C.R. Bard, Inc.
                             8.2.3.1 Company Overview
                             8.2.3.2 Financial Performance
                             8.2.3.3 Product Benchmarking
                             8.2.3.4 Strategic Initiatives
                        8.2.4 Cook Medical
                             8.2.4.1 Company Overview
                             8.2.4.2 Financial Performance
                             8.2.4.3 Product Benchmarking
                             8.2.4.4 Strategic Initiatives
                        8.2.5 ConMed Corporation
                             8.2.5.1 Company Overview
                             8.2.5.2 Financial Performance
                             8.2.5.3 Product Benchmarking
                             8.2.5.4 Strategic Initiatives
                        8.2.6 DirexGroup
                             8.2.6.1 Company Overview
                             8.2.6.2 Financial Performance
                             8.2.6.3 Product Benchmarking
                             8.2.6.4 Strategic Initiatives
                        8.2.7 Dornier MedTech GmbH
                             8.2.7.1 Company Overview
                             8.2.7.2 Financial Performance
                             8.2.7.3 Product Benchmarking
                             8.2.7.4 Strategic Initiatives
                        8.2.8 Guangzhou Potent Optotronic Technology Co., Ltd. 
                             8.2.8.1 Company Overview
                             8.2.8.2 Financial Performance
                             8.2.8.3 Product Benchmarking
                             8.2.8.4 Strategic Initiatives
                        8.2.9 HealthTronics, Inc.
                             8.2.9.1 Company Overview
                             8.2.9.2 Financial Performance
                             8.2.9.3 Product Benchmarking
                             8.2.9.4 Strategic Initiatives
                        8.2.10 Karl Storz GmbH & Co. KG
                             8.2.10.1 Company Overview
                             8.2.10.2 Financial Performance
                             8.2.10.3 Product Benchmarking
                             8.2.10.4 Strategic Initiatives
                        8.2.11 Lumenis 
                             8.2.11.1 Company Overview
                             8.2.11.2 Financial Performance
                             8.2.11.3 Product Benchmarking
                             8.2.11.4 Strategic Initiatives
                        8.2.12 Olympus Corporation
                             8.2.12.1 Company Overview
                             8.2.12.2 Financial Performance
                             8.2.12.3 Product Benchmarking
                             8.2.12.4 Strategic Initiatives
                        8.2.13 Richard Wolf
                             8.2.13.1 Company Overview
                             8.2.13.2 Financial Performance
                             8.2.13.3 Product Benchmarking
                             8.2.13.4 Strategic Initiatives
                        8.2.14 Siemens Healthcare
                             8.2.14.1 Company Overview
                             8.2.14.2 Financial Performance
                             8.2.14.3 Product Benchmarking
                             8.2.14.4 Strategic Initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 3 North America urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 4 U.S. urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 5 U.S. urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 6 Canada urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 7 Canada urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 8 Europe urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 9 Europe urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 10 UK urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 11 UK urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 12 Germany urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 13 Germany urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 14 Asia Pacific urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 15 Asia Pacific urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 16 Japan urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 17 Japan urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 18 China urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 19 China urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 20 India urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 21 India urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 22 Latin America urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 23 Latin America urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 24 Mexico urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 25 Mexico urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 26 Brazil urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 27 Brazil urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 28 MEA urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 29 MEA urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)
TABLE 30 South Africa urolithiasis management devices market, by treatment type, 2013 - 2024 (USD Million)
TABLE 31 South Africa urolithiasis management devices market, by end-use, 2013 - 2024 (USD Million)